{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:58:58Z","timestamp":1780725538520,"version":"3.54.1"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T00:00:00Z","timestamp":1343260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:p><jats:bold>Aim:\u2002<\/jats:bold> Antipsychotic medications have frequently been regarded as the treatment of choice for delirium. This study examined the clinical efficacy of risperidone for the treatment of delirium in cancer patients, combined with a repeated assessment of underlying medical severity levels.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> The study included consecutive referrals of 29 delirious cancer patients (mean age, 68.9\u2003\u00b1\u200312.5\u2003years; male, 69%) to the psychiatric consultation service. Risperidone was given orally once per day (mean dosage, 1.4\u2003\u00b1\u20031.3\u2003mg\/day). Study participants were assessed using quantitative standardized scales of cognitive function, delirium, and physical impairment at baseline and at the end of the study (seventh day).<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Risperidone with routine clinical management was effective for the treatment of delirium: 48% of the patients responded and 38% achieved remission. The reduction of delirium severity occurred in 79% of the patients. Changes in delirium severity were unrelated to age, gender, general cognitive dysfunction, or to severity of attendant medical conditions. In addition to changes in agitation and perceptional disturbances, risperidone was also effective for other specific delirium symptoms.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Risperidone with routine clinical management is effective in the treatment of delirium in advanced cancer patients, independent of changes in the underlying medical condition.<\/jats:p>","DOI":"10.1111\/j.1440-1819.2012.02346.x","type":"journal-article","created":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T10:50:22Z","timestamp":1368096622000},"page":"411-417","source":"Crossref","is-referenced-by-count":24,"title":["Treatment of delirium with risperidone in cancer patients"],"prefix":"10.1111","volume":"66","author":[{"given":"Yasuhiro","family":"Kishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Thurber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(92)90074-R"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.6.786"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(04)70170-X"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.2.231"},{"issue":"18","key":"e_1_2_6_6_2","first-page":"CD005594","article-title":"Antipsychotics for delirium","author":"Lonergan E","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.13.2.229"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(10)70725-8"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2008.06.001"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_2_6_11_2","first-page":"2","article-title":"The validity of Japanese version of Mini\u2010Mental State Examination in patients with nervous disorder","volume":"1","author":"Mori E","year":"1985","journal-title":"Shinkei Shinri"},{"key":"e_1_2_6_12_2","first-page":"217","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.100.6.1619"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(95)70202-4"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1036-7314(05)80019-0"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200601000-00005"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_6_18_2","volume-title":"Evaluation and Diagnosis of Drug\u2010Induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to Its Usage","author":"Inaba T","year":"1996"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31819b8608"},{"key":"e_1_2_6_20_2","unstructured":"HattaK.The practice of treatment for delirium in Japan. In: 6th Annual Meeting of the International College of Geriatric Psychoneuropharmacology International College of Geriatric Psychoneuropharmacology Hiroshima 2006;101."},{"key":"e_1_2_6_21_2","unstructured":"U.S. Food and Drug Administration.FDA alert. Conventional Antipsychotics \u2013 Healthcare Professional Sheet text version.2008. [Cited 16 June 2008.] Available from URL:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124830.htm(last accessed 21 March 2012)."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2008.01839.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.199"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn.2572"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.2008.20.2.185"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-8343(03)00024-0"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0510"}],"container-title":["Psychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1819.2012.02346.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1819.2012.02346.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1819.2012.02346.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T15:26:26Z","timestamp":1697297186000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1819.2012.02346.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,26]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1111\/j.1440-1819.2012.02346.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1819.2012.02346.x","archive":["Portico"],"relation":{},"ISSN":["1323-1316","1440-1819"],"issn-type":[{"value":"1323-1316","type":"print"},{"value":"1440-1819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,26]]}}}